SEC Form 4 · accession 0001479290-18-000123
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abhay Joshi
Officer — Chief Operating Officer
Period of report
Dec 14, 2018
Accepted (ET)
Dec 14, 2018 · 9:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 14, 2018 | F | 4,260 | $19.91 | D | 80,003 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares withheld by and surrendered to the issuer on December 14, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2014 Restricted Stock Award ("RSA") for 8,594 shares. The RSA vests in four equal annual installments from December 14, 2016, subject to Dr. Joshi's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date.